Prevalence and clinical significance of HER-2/neu, p53 and Rb expression in primary superficial bladder cancer

Journal of Urology

Volumn 155, Issue 5, 1996, Pages 1784-1788

  Têtu, Bernard ^a,b   Fradet, Yves ^a   Allard, Pierre ^a   Veilleux, Chantal ^a   Roberge, Nancy ^a   Bernard, Pascale ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

bladder neoplasms; carcinoma, transitional cell; genes, erbB 2; genes, p53; genes, retinoblastoma

Indexed keywords

ONCOPROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR SUPPRESSOR GENE;

EID: 0029871183     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66198-6     Document Type: Article

References (20)

1. Ro, J. Y., Staerkel, G. A. and Ayala, A. G.: Cytologic and histologic features of superficial bladder cancer. Urol. Clin. North Am., 19: 435, 1992.
2. Fradet, Y., Larue, H., Parent-Vaugeois, C., Bergeron, A., Dufour, C., Boucher, L. and Bernier, L.: Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas. Int. J. Cancer, 46: 990, 1990.
3. Yamada, T., Fukui, I., Kobayashi, T., Sekine, H., Yokogawa, M., Yamada, T. and Oshima, H.: The relationship of ABH (O) blood group antigen expression in intraepithelial dysplastic lesions to clinicopathologic properties of associated transitional cell carcinoma of the bladder. Cancer, 67: 1661, 1991.
4. Lipponen, P. K., Nordling, S., Eskelinen, M. J., Jauhiainen, K., Terho, R. and Harju, E.: Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer. Int. J. Cancer, 53: 42, 1993.
5. Sato, K., Moriyama, M., Mori, S., Saito, M., Watanuki, T., Terada, K., Okuhara, E., Akiyama, T., Toyoshima, K., Yamamoto, T. and Kato, T.: An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer, 70: 2493, 1992.
6. Lipponen, P. K.: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer, 53: 365, 1993.
7. Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W. R., Fuks, Z. and Reuter, V. E.: Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl. Cancer Inst., 84: 1251, 1992.
8. Allard, P., Fradet, Y., Têtu, B. and Bernard, P.: Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder Clin. Cancer Res., 1: 1195, 1995.
9. Hsu, S.-M., Raine, L. and Fanger, H.: Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques. A comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577, 1981.
10. Takahashi, R., Hashimoto, T., Xu, H.-J., Matsui, T., Miki, T., Bigo-Marshall, H., Aaronson, A. and Benedict, W. F.: The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc. Natl. Acad. Sci. U.S.A., 88: 5257, 1991.
11. Coombs, L. M., Pigott, D. A., Sweeney, E., Proctor, A. J., Eydmann, M. E., Parkinson, C. and Knowles, M. A.: Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br. J. Cancer, 63: 601, 1991.
12. Esrig, D., Spruck, C. H., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S.-C., Skinner, D. G., Jones, P. A. and Cote, R. J.: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143: 1389, 1993.
13. Cordon-Cardo, C., Dalbagni, G., Saez, G. T., Oliva, M. R., Zhang, Z.-F., Rosai, J., Reuter, V. E. and Pellicer, A.: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer, 56: 347, 1994.
14. Xu, H.-J., Cairns, P., Hu, S.-X., Knowles, M. A. and Benedict, W. F.: Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int. J. Cancer, 53: 781, 1993.
15. Wright, C., Mellon, K., Johnston, P., Lane, D. P., Harris, A. L., Home, C. H. W. and Neal, D. E.: Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer, 63: 967, 1991.
16. Lipponen, P. K.: Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur. J. Cancer, 29A: 749, 1993.
17. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W. and Reuter, V. E.: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85: 53, 1993.
18. Logothetis, C. J., Xu, H.-J., Ro, J. Y., Hu, S.-X., Sahin, A., Ordonez, N. and Benedict, W. F.: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl. Cancer Inst., 84: 1256, 1992.
19. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S.-C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259, 1994.
20. Vet, J. A. M., Bringuier, P. P., Poddighe, P. J., Karthaus, H. F. M., Debruyne, F. M. J. and Schalken, J. A.: p53 mutations have no additional prognostic value over stage in bladder cancer. Br. J. Cancer, 70: 496, 1994.